NDA 215401 · Noven Pharms INC
Xelstrym
Dextroamphetamine · Transdermal · Central Nervous System Stimulant
Last checked: Nov 19, 2026Latest source record: Jul 10, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Mar 22, 2022
Approved uses
1
Original approval plus efficacy supplements
Registered trials
183
36 Phase 3, 11 recruiting
FAERS reports
3,815
1,880 serious, 119 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: ABUSE, MISUSE, AND ADDICTION XELSTRYM has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including XELSTRYM, can result in overdose and death [see OVERDOSAGE (10) ] , and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection. Before prescribing XELSTRYM, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout XELSTRYM treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction [see WARNINGS AND PRECAUTIONS (5.1) and DRUG ABUSE AND DEPENDENCE (9.2) ] . WARNING: ABUSE, MISUSE, AND...
What it is approved for
From the label in effect Oct 27, 2026.
XELSTRYM ® is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older [see CLINICAL STUDIES (14) ] . Limitations of Use The use of XELSTRYM is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage [see Warnings and Precautions (5.5) , Use in Specific Populations (8.4) ]. XELSTRYM is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older ( 1 ) Limitations of Use: The use of XELSTRYM is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage ( 5.5 , 8.4 ).
Mechanism: Amphetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity. The exact mode of therapeutic action in ADHD is not known.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
4 products under this application
- XELSTRYM · DEXTROAMPHETAMINE 18MG/9HR · SYSTEM, TRANSDERMAL · Prescription
- XELSTRYM · DEXTROAMPHETAMINE 9MG/9HR · SYSTEM, TRANSDERMAL · Prescription
- XELSTRYM · DEXTROAMPHETAMINE 13.5MG/9HR · SYSTEM, TRANSDERMAL · Prescription
- XELSTRYM · DEXTROAMPHETAMINE 4.5MG/9HR · SYSTEM, TRANSDERMAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Dextroamphetamine" as an intervention, any sponsor and status, largest first.
- SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension StudyPivotal-lookingTerminated
ShireTakeda (TAK)
NCT01436175 · 1,570 participants · Start Feb 27, 2012 · Primary completion Mar 27, 2014
Drug: SPD489 (Lisdexamfetamine dimesylate) + Antidepressant · For: Major Depressive Disorder
Sites: Birmingham, Alabama; Scottsdale, Arizona; Little Rock, Arkansas · 212 sites in all
- Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive DisorderPivotal-lookingCompleted
ShireTakeda (TAK)
NCT01436149 · 1,262 participants · Start Oct 27, 2011 · Primary completion Dec 23, 2013
Drug: SPD489 (Lisdexamfetamine dimesylate ); Placebo · For: Major Depressive Disorder
Sites: Birmingham, Alabama; Carson, California; Irvine, California · 85 sites in all
- SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive DisorderPivotal-lookingCompleted
ShireTakeda (TAK)
NCT01435759 · 1,197 participants · Start May 31, 2011 · Primary completion Jan 17, 2014
Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg; Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg and 3 more · For: Major Depressive Disorder
Sites: Little Rock, Arkansas; Anaheim, California; Chino, California · 82 sites in all
- Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive DisorderPivotal-lookingCompleted
ShireTakeda (TAK)
NCT01436162 · 1,105 participants · Start Oct 19, 2011 · Primary completion Dec 10, 2013
Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate ); Antidepressant + Placebo · For: Major Depressive Disorder
Sites: Scottsdale, Arizona; Little Rock, Arkansas; Costa Mesa, California · 101 sites in all
- The Effectiveness of the Letrozole-induced Endometrial Preparation Protocol in Frozen-thawed Embryo Transfer (FET)Pivotal-lookingRecruiting
International Peace Maternity and Child Health HospitalAcademic, hospital or other
NCT06006091 · 858 participants (planned) · Start Aug 1, 2023 · Primary completion Aug 1, 2026
Drug: Letrozole · For: Letrozole; Infertility, Female
Sites: Shanghai, China
- Open Label Extension in Adults With Binge Eating Disorder (BED)Pivotal-lookingCompleted
ShireTakeda (TAK)
NCT01657019 · 604 participants · Start Aug 21, 2012 · Primary completion Oct 21, 2014
Drug: Lisdexamfetamine dimesylate · For: Binge Eating Disorder
Sites: Birmingham, Alabama; Tucson, Arizona; Little Rock, Arkansas · 89 sites in all
- Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity DisorderPivotal-lookingCompleted
ShireTakeda (TAK)
NCT01552902 · 549 participants · Start Apr 3, 2012 · Primary completion May 22, 2014
Drug: Lisdexamfetamine dimesylate; Methylphenidate Hydrochloride and 1 more · For: Attention-deficit/Hyperactivity Disorder
Sites: Dothan, Alabama; Tucson, Arizona; Little Rock, Arkansas · 95 sites in all
- Safety of SPD465 in Treating Adults With ADHD.Pivotal-lookingCompleted
ShireTakeda (TAK)
NCT00152035 · 505 participants · Start Mar 10, 2005 · Primary completion Nov 7, 2006
Drug: Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate. · For: Attention Deficit Disorder With Hyperactivity
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective386
- fatigue305
- nausea248
- anxiety235
- headache212
- depression204
- off label use186
- insomnia149
- pain149
- condition aggravated143
- dizziness143
- somnolence143
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 22 |
| 2006 | 12 |
| 2007 | 5 |
| 2008 | 18 |
| 2009 | 24 |
| 2010 | 39 |
| 2011 | 53 |
| 2012 | 87 |
| 2013 | 57 |
| 2014 | 59 |
| 2015 | 219 |
| 2016 | 576 |
| 2017 | 160 |
| 2018 | 190 |
| 2019 | 172 |
| 2020 | 158 |
| 2021 | 176 |
| 2022 | 331 |
| 2023 | 359 |
| 2024 | 455 |
| 2025 | 353 |
| 2026 | 290 |
Recalls
1 FDA enforcement reports for this application.
Oct 31, 2024 · Class II · Ongoing
Defective Delivery System: The product does not meet predetermined specifications for Coldflow (adhesive).
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Xelstrym (Dextroamphetamine)
2024 spending
$200K
Beneficiaries
131
417 claims
Per beneficiary
$1,526
$15.86 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $51,043 |
| 2024 | $199,942 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline.
Maski K, Trotti LM, Kotagal S, et al. · J Clin Sleep Med 2021 · Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Safety of Stimulants Across Patient Populations: A Meta-Analysis.
Oliva HNP, Prudente TP, Mayerson TF, et al. · JAMA Netw Open 2025 · Meta-Analysis, Research Support, N.I.H., Extramural
- Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis.
Tardelli VS, Bisaga A, Arcadepani FB, et al. · Psychopharmacology (Berl) 2020 · Meta-Analysis, Systematic Review
- Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders.
Osland ST, Steeves TD, Pringsheim T · Cochrane Database Syst Rev 2018 · Research Support, Non-U.S. Gov't, Systematic Review
- Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment.
Maski K, Trotti LM, Kotagal S, et al. · J Clin Sleep Med 2021 · Meta-Analysis, Research Support, N.I.H., Extramural
- Dextroamphetamine-morphine analgesia.
· N Engl J Med 1977 · Clinical Trial, Letter
Sponsor: Noven Pharms INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.